380 related articles for article (PubMed ID: 26147096)
1. Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.
Dominiak-Felden G; Gobbo C; Simondon F
PLoS One; 2015; 10(7):e0132404. PubMed ID: 26147096
[TBL] [Abstract][Full Text] [Related]
2. The impact of HPV multi-cohort vaccination: Real-world evidence of faster control of HPV-related morbidity.
Orumaa M; Kjaer SK; Dehlendorff C; Munk C; Olsen AO; Hansen BT; Campbell S; Nygård M
Vaccine; 2020 Feb; 38(6):1345-1351. PubMed ID: 31917039
[TBL] [Abstract][Full Text] [Related]
3. Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals.
Nygård S; Nygård M; Orumaa M; Hansen BT
Vaccine; 2023 Aug; 41(37):5469-5476. PubMed ID: 37516572
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial.
Goldstone SE; Giuliano AR; Palefsky JM; Lazcano-Ponce E; Penny ME; Cabello RE; Moreira ED; Baraldi E; Jessen H; Ferenczy A; Kurman R; Ronnett BM; Stoler MH; Bautista O; Das R; Group T; Luxembourg A; Zhou HJ; Saah A
Lancet Infect Dis; 2022 Mar; 22(3):413-425. PubMed ID: 34780705
[TBL] [Abstract][Full Text] [Related]
5. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
6. One-Dose Human Papillomavirus Vaccination and the Risk of Genital Warts: A Danish Nationwide Population-based Study.
Baandrup L; Dehlendorff C; Kjaer SK
Clin Infect Dis; 2021 Nov; 73(9):e3220-e3226. PubMed ID: 33048118
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of HPV vaccines against genital warts in women from Valencia, Spain.
Navarro-Illana E; López-Lacort M; Navarro-Illana P; Vilata JJ; Diez-Domingo J
Vaccine; 2017 Jun; 35(25):3342-3346. PubMed ID: 28499554
[TBL] [Abstract][Full Text] [Related]
8. Impact of quadrivalent human papillomavirus vaccine on genital warts in an opportunistic vaccination structure.
Lurie S; Mizrachi Y; Chodick G; Katz R; Schejter E
Gynecol Oncol; 2017 Aug; 146(2):299-304. PubMed ID: 28602548
[TBL] [Abstract][Full Text] [Related]
9. Timing of two versus three doses of quadrivalent HPV vaccine and associated effectiveness against condyloma in Sweden: a nationwide cohort study.
Lamb F; Herweijer E; Ploner A; Uhnoo I; Sundström K; Sparén P; Arnheim-Dahlström L
BMJ Open; 2017 Jun; 7(6):e015021. PubMed ID: 28600369
[TBL] [Abstract][Full Text] [Related]
10. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program.
Baandrup L; Blomberg M; Dehlendorff C; Sand C; Andersen KK; Kjaer SK
Sex Transm Dis; 2013 Feb; 40(2):130-5. PubMed ID: 23324976
[TBL] [Abstract][Full Text] [Related]
11. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
[TBL] [Abstract][Full Text] [Related]
12. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.
Leval A; Herweijer E; Ploner A; Eloranta S; Fridman Simard J; Dillner J; Young C; Netterlid E; Sparén P; Arnheim-Dahlström L
J Natl Cancer Inst; 2013 Apr; 105(7):469-74. PubMed ID: 23486550
[TBL] [Abstract][Full Text] [Related]
13. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium.
Demarteau N; Van Kriekinge G; Simon P
Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952
[TBL] [Abstract][Full Text] [Related]
14. Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550,000 Young Girls.
Blomberg M; Dehlendorff C; Sand C; Kjaer SK
Clin Infect Dis; 2015 Sep; 61(5):676-82. PubMed ID: 25944340
[TBL] [Abstract][Full Text] [Related]
15. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark.
Blomberg M; Dehlendorff C; Munk C; Kjaer SK
Clin Infect Dis; 2013 Oct; 57(7):929-34. PubMed ID: 23804192
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data.
Donovan B; Franklin N; Guy R; Grulich AE; Regan DG; Ali H; Wand H; Fairley CK
Lancet Infect Dis; 2011 Jan; 11(1):39-44. PubMed ID: 21067976
[TBL] [Abstract][Full Text] [Related]
17. Impact of the human papillomavirus (HPV) vaccine on genital wart diagnoses at Auckland Sexual Health Services.
Oliphant J; Perkins N
N Z Med J; 2011 Jul; 124(1339):51-8. PubMed ID: 21952330
[TBL] [Abstract][Full Text] [Related]
18. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review.
Mariani L; Vici P; Suligoi B; Checcucci-Lisi G; Drury R
Adv Ther; 2015 Jan; 32(1):10-30. PubMed ID: 25620536
[TBL] [Abstract][Full Text] [Related]
19. The early benefits of human papillomavirus vaccination on cervical dysplasia and anogenital warts.
Smith LM; Strumpf EC; Kaufman JS; Lofters A; Schwandt M; Lévesque LE
Pediatrics; 2015 May; 135(5):e1131-40. PubMed ID: 25917991
[TBL] [Abstract][Full Text] [Related]
20. The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus.
McClymont E; Lee M; Raboud J; Coutlée F; Walmsley S; Lipsky N; Loutfy M; Trottier S; Smaill F; Klein MB; Harris M; Cohen J; Yudin MH; Wobeser W; Money D;
Clin Infect Dis; 2019 Feb; 68(5):788-794. PubMed ID: 29985988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
